Destiny Pharma PLC's (LON:DEST) Neil Clarke talks to Proactive London's Katie Pilbeam about the XF-73 Phase 2b clinical trial which is now fully recruited.
The plan is to finalise the phase 2 data in the first quarter then move on to phase 3, with discussions already taking place as to how this is going to work, in regards to the amount of patients that will be taking part.
Destiny is focused on medicines that can prevent life-threatening infections after operations in hospitals. XF-73 is designed to prevent post-surgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus (MRSA).